Sponsor study identifier
observational
291
1 country
1
Study Start
May 2, 2024
Actual (reported)Primary Completion
December 31, 2024
Actual (reported)Study Completion
December 31, 2024
Actual (reported)Background: Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality among dialysis patients. Eotaxin-1(also known as Eotaxin and CCL11), an eosinophil-specific chemoattractant that plays a role in a variety of pathologic conditions including allergy, coronary heart disease, and inflammatory bowel disease. CCL11 has been shown to be overexpressed in human atherosclerotic lesions. Moreover, eotaxin-1 levels are higher in non-uremic coronary artery disease patients than in healthy individuals. Methods: The study will enrolled 400 hemodialysis patients. Patients are diagnosed with coronary artery disease based on clinical presentation and confirmed by angiography. Serum eotaxin-1 and 8-isoprostane levels are determined by enzyme-linked immunosorbent assay (ELISA). High-sensitivity cTnI immunoassays and albumin redox state by high-performance liquid chromatography are used for measurements. Aim: In this study, we aimed to determine the eotaxin-1 concentrations of patients with coronary artery disease and to investigate the role of eotaxin-1 and markers of myocardial injury.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2024
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 8, 2024
Actual (reported)January 18, 2024
Actual (reported)May 2, 2024
Actual (reported)December 31, 2024
Actual (reported)December 31, 2024
Actual (reported)Analysis of biomarkers of serum eotaxin levels.
Eotaxin levels and the serum levels of markers of myocardial injury as well as oxidative stress in a group of prevalent hemodialysis patients.
1 years
Redox state of serum albumin assays
1 years
Analysis of biomarkers of MCP-1
1 years
Analysis of biomarkers of IL-6
1 years
Analysis of biomarkers of 8-isoprostane
1 years
Analysis of biomarkers of High Sensitivity Troponin I
1 years
patients have to be at least 20-years-old and on outpatient hemodialysis (HD) for at least 3 months.
Tungs' Taichung MetroHarbour Hospital
Taichung, Taiwan
serum
Paik Seong Lim, PhD
Tungs' Taichung Metroharbour Hospital
291 participants (actual enrollment reported by the registry).
First Submitted
January 8, 2024
First Posted
January 18, 2024
Study Start
May 2, 2024
Actual (reported)Comparative Analysis of NTG-Pd/Pa and Saline-Pd/Pa (CANS)
Contact the study team to confirm eligibility.
Primary Completion
December 31, 2024
Actual (reported)Study Completion
December 31, 2024
Actual (reported)Last Updated
June 6, 2025
Record last verified: 2025-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: